Evidence map›Paper›PMID 24674583›Full record

ArticleComparative medicine2014

Urinary MCP1 and Microalbumin increase prior to onset of Azotemia in mice with polycystic kidney disease.

Naomi A Kirby, Aaron M Stepanek, Andyna Vernet, Sarah M Schmidt, Carrie L Schultz, Nicola Ma Parry, Steven M Niemi, James G Fox, Diane E Brown

Open access · greenAbstract read
In one paragraph

Article in Comparative medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Naomi A KirbyCenter for Comparative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Aaron M StepanekCenter for Comparative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Andyna VernetCenter for Comparative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Sarah M SchmidtCenter for Comparative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Carrie L SchultzPurina LabDiet, St Louis, Missouri, USA.
Nicola Ma ParryDivision of Comparative Medicine, Massachusetts Institute of Technology, Boston, Massachusetts, USA.
Steven M NiemiCenter for Comparative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
James G FoxDivision of Comparative Medicine, Massachusetts Institute of Technology, Boston, Massachusetts, USA.
Diane E BrownCenter for Comparative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. dbrown31@partners.org.
Massachusetts General Hospital · USMassachusetts Institute of Technology · US

Funding

Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LEVINE, STUART S · 1985 to 2020
$25.6M
NCATS NIH HHS 8UL1TR000170-05NCATS NIH HHS UL1 TR000170NIEHS NIH HHS P30 ES002109
6 · The paper itself

Abstract

Urinary biomarkers may offer a more sensitive and less invasive means to monitor kidney disease than traditional blood chemistry biomarkers such as creatinine. CD1(pcy/pcy) (pcy) mice have a slowly progressive disease phenotype that resembles human autosomal dominant polycystic kidney disease with renal cyst formation and inflammation. Previous reports suggest that dietary protein restriction may slow disease progression in mice and humans with polycystic kidney disease. Accordingly, we fed pcy mice either a standard chow (22.5% protein) or a protein-restricted (11.5% soy-based protein) diet from weaning until 34 wk of age. Every 6 wk we measured markers of kidney disease, including serum creatinine, BUN, and serum albumin as well as urinary monocyte chemoattractant protein 1 (MCP1), microalbumin, and specific gravity. Progression of kidney disease was equivalent for both diet groups despite dietary protein restriction. Urinary biomarkers proved useful for early detection of disease, in that urinary microalbumin was elevated as early as 22 wk of age and urinary MCP1 was increased by 28 wk of age, whereas increases in serum creatinine and BUN were detected later (at 34 wk of age) in both diet groups. Thus, urinary microalbumin and MCP1 analyses provided earlier, noninvasive indicators for detection of kidney disease and disease progression in pcy mice than did serum creatinine and BUN.

Indexed as

AlbuminuriaAnalysis of VarianceAnimalsAzotemiaBiomarkersBlood Urea NitrogenChemokine CCL2CreatinineDiet, Protein-RestrictedMicePolycystic Kidney DiseasesSerum AlbuminBiomarkersChemokine CCL2CreatinineSerum Albumin

Identifiers

PMID24674583
PMCPMC3997286
OpenAlexW2128761254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.